Reprogramming of Glutamine Amino Acid Transporters Expression and Prognostic Significance in Hepatocellular Carcinoma
View abstract on PubMed
Summary
This summary is machine-generated.Hepatocellular carcinoma (HCC) cells rely on glutamine for growth, showing altered transporter expression compared to normal liver cells. Targeting these glutamine transporters impacts HCC cell survival and offers prognostic insights.
Area Of Science
- Oncology
- Molecular Biology
- Biochemistry
Background
- Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality worldwide.
- Understanding metabolic dependencies in HCC is crucial for developing targeted therapies.
Purpose Of The Study
- To investigate glutamine amino acid transporter expression in HCC versus normal liver cells.
- To determine the prognostic significance of these transporters in HCC patients.
Main Methods
- Utilized quantitative PCR (qPCR) and RNA sequencing (RNAseq) on in vitro and in vivo HCC models and patient tumors.
- Employed siRNA and gamma-p-nitroanilide (GPNA) to target specific solute carrier (SLC) transporters.
- Assessed glutamine uptake rates in HCC cells.
Main Results
- HCC cells exhibit increased glutamine uptake compared to normal hepatocytes.
- A significant reprogramming of glutamine transporters (SLC) was observed in HCC, with decreased SLC38A3 and increased SLC38A1, SLC7A6, and SLC1A5.
- Altered expression levels of SLC6A14, SLC38A3, SLC38A1, SLC7A6, and SLC1A5 correlated with patient survival outcomes.
- Targeting SLC1A5 and SLC38A2 significantly reduced glutamine uptake in HCC cells, with combined targeting showing the greatest effect.
Conclusions
- Glutamine transporter reprogramming is a novel hallmark of HCC.
- The expression profiles of glutamine transporters are clinically significant and hold prognostic value in HCC.
- Targeting glutamine transporters represents a potential therapeutic strategy for HCC.

